{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T14:19:36Z","timestamp":1778681976919,"version":"3.51.4"},"reference-count":31,"publisher":"Pharmaceutical Society of Japan","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological &amp; Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2018,7,1]]},"DOI":"10.1248\/bpb.b18-00164","type":"journal-article","created":{"date-parts":[[2018,5,10]],"date-time":"2018-05-10T22:27:52Z","timestamp":1525991272000},"page":"1112-1118","source":"Crossref","is-referenced-by-count":26,"title":["Necessity for a Significant Maintenance Dosage Reduction of Voriconazole in Patients with Severe Liver Cirrhosis (Child\u2013Pugh Class C)"],"prefix":"10.1248","volume":"41","author":[{"given":"Takehiro","family":"Yamada","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Hokkaido University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shungo","family":"Imai","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Hokkaido University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuyuki","family":"Koshizuka","sequence":"additional","affiliation":[{"name":"Department of Gastroenterological Surgery I, Hokkaido University Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Tazawa","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Hokkaido University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keisuke","family":"Kagami","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Hokkaido University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Tomiyama","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Hokkaido University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryosuke","family":"Sugawara","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Hokkaido University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Yamagami","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Hokkaido University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsuyoshi","family":"Shimamura","sequence":"additional","affiliation":[{"name":"Division of Organ Transplantation, Hokkaido University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Iseki","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Hokkaido University Hospital"},{"name":"Division of Pharmasciences, Faculty of Pharmaceutical Sciences, Laboratory of Clinical Pharmaceutics and Therapeutics"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"163","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Espinel-Ingroff A. <i>In vitro<\/i> activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens. <i>J. Clin. Microbiol.<\/i>, <b>36<\/b>, 198\u2013202 (1998).","DOI":"10.1128\/JCM.36.1.198-202.1998"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Karthaus M. Prophylaxis and treatment of invasive aspergillosis with voriconazole, posaconazole and caspofungin-review of the literture. <i>Eur. J. Med. Res.<\/i>, <b>16<\/b>, 145\u2013152 (2011).","DOI":"10.1186\/2047-783X-16-4-145"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Lazarus HM, Blumer JL, Yanovich S, Schlamm H, Romero A. Safety and pharmacokinetics of oral voriconazole in patients at risk of fungal infection: a dose escalation study. <i>J. Clin. Pharmacol.<\/i>, <b>42<\/b>, 395\u2013402 (2002).","DOI":"10.1177\/00912700222011445"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Saravolatz LD, Johnson LB, Kauffman CA. Voriconazole: a new triazole antifungal agent. <i>Clin. Infect. Dis.<\/i>, <b>36<\/b>, 630\u2013637 (2003).","DOI":"10.1086\/367933"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Matsumoto K, Ikawa K, Abematsu K, Fukunaga N, Nishida K, Fukamizu T, Shimodozono Y, Morikawa N, Takeda Y, Yamada K. Correlation between voriconazole trough plasma concentration and hepatotoxicity in patients with different CYP2C19 genotypes. <i>Int. J. Antimicrob. Agents<\/i>, <b>34<\/b>, 91\u201394 (2009).","DOI":"10.1016\/j.ijantimicag.2009.01.008"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Laverdiere M, Bow EJ, Rotstein C, Autmizguine J, Broady R, Garber G, Haider S, Hussaini T, Husain S, Ovetchkine P, Seki JT, Th\u00e9or\u00eat Y. Therapeutic drug monitoring for triazoles: A needs assessment review and recommendations from a Canadian perspective. <i>Can. J. Infect. Dis. Med. Microbiol.<\/i>, <b>25<\/b>, 327\u2013343 (2014).","DOI":"10.1155\/2014\/340586"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Hamada Y, Seto Y, Yago K, Kuroyama M. Investigation and threshold of optimum blood concentration of voriconazole: a descriptive statistical meta-analysis. <i>J. Infect. Chemother.<\/i>, <b>18<\/b>, 501\u2013507 (2012).","DOI":"10.1007\/s10156-011-0363-6"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Ueda K, Nannya Y, Kumano K, Hangaishi A, Takahashi T, Imai Y, Kurokawa M. Monitoring trough concentration of voriconazole is important to ensure successful antifungal therapy and to avoid hepatic damage in patients with hematological disorders. <i>Int. J. Hematol.<\/i>, <b>89<\/b>, 592\u2013599 (2009).","DOI":"10.1007\/s12185-009-0296-3"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Hamada Y, Tokimatsu I, Mikamo H, Kimura M, Seki M, Takakura S, Ohmagari N, Takahashi Y, Kasahara K, Matsumoto K, Okada K, Igarashi M, Kobayashi M, Mochizuki T, Nishi Y, Tanigawara Y, Kimura T, Takesue Y. Practice guidelines for therapeutic drug monitoring of voriconazole: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring. <i>J. Infect. Chemother.<\/i>, <b>19<\/b>, 381\u2013392 (2013).","DOI":"10.1007\/s10156-013-0607-8"},{"key":"10","unstructured":"10) \u201cVFEND prescriving information for voriconazole tablet, film coated.\u201d \u2039http:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=618; 2017\u203a, cited 11 December, 2017."},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Weiler S, Zoller H, Graziadei I, Vogel W, Bellmann-Weiler R, Joannidis M, Bellmann R. Altered pharmacokinetics of voriconazole in a patient with liver cirrhosis. <i>Antimicrob. Agents Chemother.<\/i>, <b>51<\/b>, 3459\u20133460 (2007).","DOI":"10.1128\/AAC.00791-07"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Balogh J, Burroughs SG, Boktour M, Patel S, Saharia A, Ochoa RA, McFadden R, Victor DW, Ankoma-Sey V, Galati J, Monsour HP Jr, Fainstein VF, Li XC, Grimes KA, Gaber AO, Aloia T, Ghobrial RM. Efficacy and cost-effectiveness of voriconazole prophylaxis for prevention of invasive aspergillosis in high-risk liver transplant recipients. <i>Liver Transpl.<\/i>, <b>22<\/b>, 163\u2013170 (2016).","DOI":"10.1002\/lt.24365"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Jeurissen S, Vogelaers D, Sermijn E, Van Dycke K, Geerts A, Van Vlierberghe H, Colle I. Invasive aspergillosis in patients with cirrhosis, a case report and review of the last 10 years. <i>Acta Clin. Belg.<\/i>, <b>68<\/b>, 368\u2013375 (2013).","DOI":"10.2143\/ACB.3408"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Patterson TF, Thompson GR III, Denning DW, Fishman JA, Hadley S, Herbrecht R, Kontoyiannis DP, Marr KA, Morrison VA, Nguyen MH, Segal BH, Steinbach WJ, Stevens DA, Walsh TJ, Wingard JR, Young JAH, Bennett JE. Practice guidelines for the diagnosis and management of Aspergillosis: 2016 update by the Infectious Diseases Society of America. <i>Clin. Infect. Dis.<\/i>, <b>63<\/b>, e1\u2013e60 (2016).","DOI":"10.1093\/cid\/ciw326"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Barchiesi F, Mazzocato S, Mazzanti S, Gesuita R, Skrami E, Fiorentini A, Singh N. Invasive Aspergillosis in liver transplant recipients: epidemiology, clinical characteristics, treatment, and outcomes in 116 cases. <i>Liver Transpl.<\/i>, <b>21<\/b>, 204\u2013212 (2015).","DOI":"10.1002\/lt.24032"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Dolton MJ, Ray JE, Chen SC, Ng K, Pont LG, McLachlan AJ. Multicenter study of voriconazole pharmacokinetics and therapeutic drug monitoring. <i>Antimicrob. Agents Chemother.<\/i>, <b>56<\/b>, 4793\u20134799 (2012).","DOI":"10.1128\/AAC.00626-12"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Dote S, Sawai M, Nozaki A, Naruhashi K, Kobayashi Y, Nakanishi H. A retrospective analysis of patient-specific factors on voriconazole clearance. <i>J. Pharm. Health Care Sci.<\/i>, <b>2<\/b>, 10 (2016).","DOI":"10.1186\/s40780-016-0044-9"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Qi F, Zhu L, Li N, Ge T, Xu G, Liao S. Influence of different proton pump inhibitors on the pharmacokinetics of voriconazole. <i>Int. J. Antimicrob. Agents<\/i>, <b>49<\/b>, 403\u2013409 (2017).","DOI":"10.1016\/j.ijantimicag.2016.11.025"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Niece KL, Boyd NK, Akers KS. <i>In vitro<\/i> study of the variable effects of proton pump inhibitors on voriconazole. <i>Antimicrob. Agents Chemother.<\/i>, <b>59<\/b>, 5548\u20135554 (2015).","DOI":"10.1128\/AAC.00884-15"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Cojutti P, Candoni A, Forghieri F, Isola M, Zannier ME, Bigliardi S, Luppi M, Fanin R, Pea F. Variability of voriconazole trough levels in haematological patients: influence of comedications with cytochrome P450 (CYP) inhibitors and\/or with CYP inhibitors plus CYP inducers. <i>Basic Clin. Pharmacol. Toxicol.<\/i>, <b>118<\/b>, 474\u2013479 (2016).","DOI":"10.1111\/bcpt.12530"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Gage R, Stopher DA. A rapid HPLC assay for voriconazole in human plasma. <i>J. Pharm. Biomed. Sci.<\/i>, <b>17<\/b>, 1449\u20131453 (1998).","DOI":"10.1016\/S0731-7085(98)00004-1"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Papp M, Vitalis Z, Altorjay I, Tornai I, Udvardy M, Harsfalvi J, Vida A, Kappelmayer J, Lakatos PL, Antal-Szalmas P. Acute phase proteins in the diagnosis and prediction of cirrhosis associated bacterial infections. <i>Liver<\/i>, <b>32<\/b>, 603\u2013611 (2012).","DOI":"10.1111\/j.1478-3231.2011.02689.x"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Aitken AE, Morgan ET. Gene-specific effects of inflammatory cytokines on cytochrome P450 2C, 2B6 and 3A4 mRNA levels in human hepatocytes. <i>Drug Metab. Dispos.<\/i>, <b>35<\/b>, 1687\u20131693 (2007).","DOI":"10.1124\/dmd.107.015511"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Veringa A, ter Avest M, Span LFR, van den Heuvel ER, Touw DJ, Zijlstra JG, Kosterink JGW, van der Werf TS, Alffenaar JWC. Voriconazole metabolism is influenced by severe inflammation: a prospective study. <i>J. Antimicrob. Chemother.<\/i>, <b>72<\/b>, 261\u2013267 (2017).","DOI":"10.1093\/jac\/dkw349"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) da Silva Silvestre JP, da Cruz Coelho LM, P\u00f3voa PMSR. Impact of fulminant hepatic failure in C-reactive protein? <i>J. Crit. Care<\/i>, <b>25<\/b>, 657.e7\u2013657.e12 (2010).","DOI":"10.1016\/j.jcrc.2010.02.004"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Lelubre C, Anselin S, Boudjeltia KZ, Biston P, Piagnerelli M. Interpretation of C-reactive protein concentrations in critically ill patients. <i>Biomed. Res. Int.<\/i>, <b>2013<\/b>, 124021 (2013).","DOI":"10.1155\/2013\/124021"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Hafner V, Czock D, Burhenne J, Riedel KD, Bommer J, Mikus G, Machleidt C, Weinreich T, Haefeli WE. Pharmacokinetics of sulfobutylether-beta-cyclodextrin and voriconazole in patients with end-stage renal failure during treatment with two hemodialysis systems and hemodiafiltration. <i>Antimicrob. Agents Chemother.<\/i>, <b>54<\/b>, 2596\u20132602 (2010).","DOI":"10.1128\/AAC.01540-09"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Kiser TH, Fish DN, Aquilante CL, Rower JE, Wempe MF, MacLaren R, Teitelbaum I. Evaluation of sulfobutylether-\u03b2-cyclodextrin (SBECD) accumulation and voriconazole pharmacokinetics in critically ill patients undergoing continuous renal replacement therapy. <i>Crit. Care<\/i>, <b>19<\/b>, 32 (2015).","DOI":"10.1186\/s13054-015-0753-8"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Spriet I, Br\u00fcggemann RJM, Annaert P, Meersseman P, Van Wijngaerden E, Lagrou K, Willems L. Pharmacokinetic profile of voriconazole in a critically ill patient on therapeutic plasma exchange. <i>Ther. Drug Monit.<\/i>, <b>35<\/b>, 141\u2013143 (2013).","DOI":"10.1097\/FTD.0b013e31827d76b0"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Mizutani T. PM frequencies of major CYPs in Asians and Caucasians. <i>Drug Metab. Rev.<\/i>, <b>35<\/b>, 99\u2013106 (2003).","DOI":"10.1081\/DMR-120023681"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Yamada T, Mino Y, Yagi T, Naito T, Kawakami J. Saturated metabolism of voriconazole <i>N<\/i>-oxidation resulting in nonlinearity of pharmacokinetics of voriconazole at clinical doses. <i>Biol. Pharm. Bull.<\/i>, <b>38<\/b>, 1496\u20131503 (2015).","DOI":"10.1248\/bpb.b15-00241"}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/41\/7\/41_b18-00164\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T21:18:02Z","timestamp":1604265482000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/41\/7\/41_b18-00164\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,1]]},"references-count":31,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b18-00164","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,1]]}}}